These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9725477)

  • 1. Comparative bioavailability of two oral formulations of ipriflavone in healthy volunteers at steady-state. Evaluation of two different dosage schemes.
    Acerbi D; Poli G; Ventura P
    Eur J Drug Metab Pharmacokinet; 1998; 23(2):172-7. PubMed ID: 9725477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet.
    Rohatagi S; Barrett JS; Sawyers W; Yu K; Morales RJ
    Am J Ther; 1997; 4(7-8):229-38. PubMed ID: 10423615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated pharmacokinetic and metabolic modeling of ipriflavone and metabolites after oral administration.
    Rohatagi S; Barrett JS
    Am J Ther; 1997; 4(5-6):189-98. PubMed ID: 10423610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
    Kim SH; Lee MG
    Life Sci; 2002 Feb; 70(11):1299-315. PubMed ID: 11883708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and tissue distribution of ipriflavone, an isoflavone derivative, after intravenous administration to rabbits.
    Kim S; Lee J; Lee M
    Biopharm Drug Dispos; 2000 May; 21(4):147-56. PubMed ID: 11180193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of a isoflavone derivative, ipriflavone, and its metabolites, M1 and M5, in rat plasma, urine, and tissue homogenate by high-performance liquid chromatography.
    Kim SH; Lee JS; Lee MG
    Res Commun Mol Pathol Pharmacol; 1997 Dec; 98(3):313-24. PubMed ID: 9485525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state pharmacokinetics of ipriflavone and its metabolites in patients with renal failure.
    Rondelli I; Acerbi D; Ventura P
    Int J Clin Pharmacol Res; 1991; 11(4):183-92. PubMed ID: 1813437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects.
    Gordi T; Hou E; Kasichayanula S; Berner B
    Clin Ther; 2008 May; 30(5):909-16. PubMed ID: 18555937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative pharmacokinetics of three oral 400 mg ibuprofen dosage forms in healthy volunteers.
    Saano V; Paronen P; Peura P; Vidgren M
    Int J Clin Pharmacol Ther Toxicol; 1991 Oct; 29(10):381-5. PubMed ID: 1748537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability and urinary excretion of isoflavones in humans: effects of soy-based supplements formulation and equol production.
    Vergne S; Titier K; Bernard V; Asselineau J; Durand M; Lamothe V; Potier M; Perez P; Demotes-Mainard J; Chantre P; Moore N; Bennetau-Pelissero C; Sauvant P
    J Pharm Biomed Anal; 2007 Mar; 43(4):1488-94. PubMed ID: 17110073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of pregabalin in healthy volunteers.
    Bockbrader HN; Radulovic LL; Posvar EL; Strand JC; Alvey CW; Busch JA; Randinitis EJ; Corrigan BW; Haig GM; Boyd RA; Wesche DL
    J Clin Pharmacol; 2010 Aug; 50(8):941-50. PubMed ID: 20147618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of nifedipine from different oral dosage forms in healthy volunteers.
    Leucuţa SE; Vida-Simiti L; Căprioară MG; Făgărăşan E; Olinic N; Manasia M; Vlaicu R
    Pharmazie; 1989 May; 44(5):336-8. PubMed ID: 2772014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of E. Coli lipopolysaccharide on the pharmacokinetics of ipriflavone and its metabolites, M1 and M5, after intravenous and oral administration of ipriflavone to rats: decreased metabolism of ipriflavone due to decreased expression of hepatic CYP1A2 and 2C11.
    Chung HJ; Kang HE; Bae EJ; Lee I; Kim SG; Lee MG
    J Pharm Sci; 2008 Nov; 97(11):5024-36. PubMed ID: 18314883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin.
    Lee DY; Chung HJ; Choi YH; Lee U; Kim SH; Lee I; Lee MG
    Eur J Pharm Sci; 2009 Dec; 38(5):465-71. PubMed ID: 19761842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women.
    Anupongsanugool E; Teekachunhatean S; Rojanasthien N; Pongsatha S; Sangdee C
    BMC Clin Pharmacol; 2005 Mar; 5():2. PubMed ID: 15743537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
    Maurer JM; Schellekens RC; van Rieke HM; Stellaard F; Wutzke KD; Buurman DJ; Dijkstra G; Woerdenbag HJ; Frijlink HW; Kosterink JG
    J Control Release; 2013 Dec; 172(3):618-24. PubMed ID: 24096020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High performance liquid chromatographic method for the determination of ipriflavone in serum and its pharmacokinetic study in healthy volunteers].
    Ma XH; Xu Y; Liu TP
    Yao Xue Xue Bao; 1997 Jun; 32(6):470-2. PubMed ID: 11596332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
    Guivarc'h PH; Vachon MG; Fordyce D
    Clin Ther; 2004 Sep; 26(9):1456-69. PubMed ID: 15531008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.